BeOne Medicines (ONC) Short-Term Debt issuances (2017 - 2026)

BeOne Medicines (ONC) has 8 years of Short-Term Debt issuances data on file, last reported at $58.2 million in Q1 2026.

• On a quarterly basis, Short-Term Debt issuances fell 66.34% year-over-year to $58.2 million in Q1 2026; TTM through Mar 2026 was $930.1 million, a 10.67% decrease from a year earlier, with the FY2025 full-year figure at $1.0 billion, up 20.33% from the prior year.
• Short-Term Debt issuances for Q1 2026 stood at $58.2 million, down from $769.0 million in the prior quarter.
• Over the last five years, Short-Term Debt issuances for ONC reached as high as $769.0 million in Q4 2025 and fell as low as -$2.3 million in Q3 2023.
• Historically, Short-Term Debt issuances has averaged $192.7 million across 5 years, with a median of $107.4 million in 2023.
• Across the five-year window, Short-Term Debt issuances slumped 107.56% in 2023 and surged 373.85% in 2024, its largest moves.
• Year by year, Short-Term Debt issuances stood at $271.7 million in 2022, then plunged by 44.78% to $150.0 million in 2023, then jumped by 373.85% to $710.8 million in 2024, then gained by 8.19% to $769.0 million in 2025, then slumped by 92.43% to $58.2 million in 2026.
• Per Business Quant data, the three most recent Short-Term Debt issuances figures were $58.2 million in Q1 2026, $769.0 million in Q4 2025, and $102.9 million in Q2 2025.